Key result
Prompt high-dose corticosteroids linked to improved outcomes in life-threatening ICI-associated myocarditis.
Why the study?
As immune checkpoint inhibitors are increasingly used across earlier disease stages, prolonged durations, and combination regimens, the clinical burden of rare but life-threatening myocarditis is expected to rise.
Design
Review
Answers are grounded in this paper and cite their sources.
Requires prompt high-dose corticosteroids with early ICI-myocarditis recognition; reinforces rapid immunosuppression as standard in cardio-oncology.
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of multiple malignancies but are increasingly associated with immune-related cardiovascular toxicities. Among these, ICI-associated myocarditis is rare yet represents the most severe and life-threatening cardiac adverse event, characterized by early onset, malignant arrhythmias, conduction disturbances, acute heart failure, and high mortality. As ICIs are increasingly administered across earlier disease stages, prolonged durations, and combination regimens, the clinical burden of myocarditis is expected to rise. Pathogenesis is driven by dysregulated T-cell–mediated immune activation, loss of peripheral tolerance, and shared tumor–cardiac antigens, with heightened risk observed in patients receiving dual immune checkpoint blockade. Diagnosis remains challenging due to nonspecific symptoms, frequent preservation of left ventricular function, and limited sensitivity of early cardiac imaging, necessitating a multimodal approach integrating cardiac biomarkers, electrocardiography, advanced imaging, and selective endomyocardial biopsy. Early recognition and prompt initiation of high-dose corticosteroids are central to management and are associated with improved outcomes, while steroid-refractory cases may require targeted immunomodulatory therapies. Decisions regarding ICI rechallenge remain complex and must balance oncologic benefit against the risk of recurrent cardiac injury. Optimal care in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Thukral et al. (2026) studied this question. Early recognition and prompt initiation of high-dose corticosteroids improve outcomes in patients with rare but life-threatening immune checkpoint inhibitor-associated myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: